Individuals with radiologic evidence vertebral bone loss. Individuals who are receiving or will be receiving glucocorticoid therapy equivalent to 7.5 mg. of prednisone or greater daily for more than three months. Individuals with primary hyperparathyroidism. Individuals being monitored to assess the efficacy of an FDA approved drug for osteoporosis. Individuals with conditions that induce secondary risk of osteoporosis including hyperparathyroidism, hyperthyroidism, Cushing's syndrome, malabsorption and long-term use of steroids, heparin or anticonvulsant hydantoin derivatives.
Renal osteodystrophy is also an indication.
History of bone fracture with minor trauma in post-menopausal women or men with hypogonadism. Individuals with documented loss of height 1.5 inches or more. Individuals with a history of unexplained bone pain. In this instance, there must be some prior workup to exclude other causes. History of hypogonadism in men.